Vγ9Vδ2 T cells

Vγ9Vδ2 T cells are a distinct subset of human γδ (gamma delta) T lymphocytes characterized by their expression of the Vγ9 and Vδ2 chains in their T cell receptor (TCR). They represent the predominant γδ T cell population in adult human peripheral blood. These cells recognize non-peptidic phosphoantigens independently of major histocompatibility complex (MHC) molecules and play a critical role in immune surveillance against infections and tumors. In cancer immunotherapy, adoptive transfer or ex vivo expansion of autologous or allogeneic Vγ9Vδ2 T cells is being explored for hematological malignancies and solid tumors. Their mechanisms include direct cytotoxicity via perforin/granzyme pathways, antibody-dependent cellular cytotoxicity (ADCC), cytokine production (e.g., IFN-γ, TNF-α), cross-presentation of tumor antigens to CD8+ αβTCR+ cytotoxic lymphocytes, and immune regulation through interactions with B-cells and dendritic cells. Clinical trials have tested zoledronate-expanded autologous or allogeneic infusions for cancers such as non-small cell lung cancer (NSCLC) and multiple myeloma; genetic engineering approaches like CAR-modified Vγ9Vδ2 are also under investigation[1][6][7].

Other names

Vgamma9Vdelta2 T cellsVgamma-9Vdelta2 T cellsVgamma 9Vdelta2 T cellshuman Vγ9Vδ2 T lymphocytes